BRPI0520902A2 - Anticorpo monoclonal ou fragmento de ligação a antigeno do mesmo que se liga a proteinas psca para disgnostico de cancer, metodo para produção dos mesmos, hib'ridoma, polinucleotideo, vetor, celula, composição, ensaio para detectar a presença de uma proteina'psca e metodo de detecção de uma proteina psca - Google Patents

Anticorpo monoclonal ou fragmento de ligação a antigeno do mesmo que se liga a proteinas psca para disgnostico de cancer, metodo para produção dos mesmos, hib'ridoma, polinucleotideo, vetor, celula, composição, ensaio para detectar a presença de uma proteina'psca e metodo de detecção de uma proteina psca

Info

Publication number: BRPI0520902A2
Authority: BR; Brazil
Prior art keywords: psca; psca protein; ridoma; hib; polynucleotide
Prior art date: 2004-05-28

Application number

Other languages

English (en)

Inventor

Jean Gudas

Aya Jakobovits

Xiao-Chi Jia

Robert Kendall Morrison

Karen Jane Meyrick Morrison

Hui Shao

Pia M Challita-Eid

Arthur B Raitano

Original Assignee

Agensys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-28

Filing date

2005-05-17

Publication date

2011-10-25

2004-05-28 Priority claimed from US10/857,484 external-priority patent/US7622564B2/en

2005-05-17 Application filed by Agensys Inc filed Critical Agensys Inc

2005-05-17 Priority claimed from PCT/US2005/017412 external-priority patent/WO2005118864A2/en

2011-10-25 Publication of BRPI0520902A2 publication Critical patent/BRPI0520902A2/pt

2021-11-30 Publication of BRPI0520902B1 publication Critical patent/BRPI0520902B1/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Cell Biology (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Plant Pathology (AREA)
Peptides Or Proteins (AREA)

BRPI0520902-1A 2004-05-28 2005-05-17 Anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo que se liga a proteínas psca para diagnóstico de câncer, método para produção dos mesmos, hibridoma, polinucleotídeo, vetor, composição, ensaio para detectar a presença de uma proteína psca e método de detecção de uma proteína psca BRPI0520902B1 (pt)

Applications Claiming Priority (14)

Application Number	Priority Date	Filing Date	Title
US10/857,484 US7622564B2 (en)	2003-05-30	2004-05-28	Prostate stem cell antigen (PSCA) variants and subsequences thereof
PCT/US2004/017231 WO2005014780A2 (en)	2003-05-30	2004-05-28	Prostate stem cell antigen (psca) variants and subsequences thereof
US61638104P	2004-10-05	2004-10-05
US60/616,381		2004-10-05
US61788104P	2004-10-12	2004-10-12
US60/617,881		2004-10-12
US62131004P	2004-10-21	2004-10-21
US60/621,310		2004-10-21
US63307704P	2004-12-02	2004-12-02
US60/633,077		2004-12-02
US67200005P	2005-04-14	2005-04-14
US60/672,000		2005-04-14
BRPI0511624-4A BRPI0511624B1 (pt)	2004-05-28	2005-05-17	Anticorpo monoclonal que se liga à proteína psca, uso do mesmo, hibridoma, vetor, composição farmacêutica, bem como ensaio e método para detecção da presença de uma proteína psca em uma amostra biológica
PCT/US2005/017412 WO2005118864A2 (en)	2004-05-28	2005-05-17	Antibodies and related molecules that bind to psca proteins

Publications (2)

Publication Number	Publication Date
BRPI0520902A2 true BRPI0520902A2 (pt)	2011-10-25
BRPI0520902B1 BRPI0520902B1 (pt)	2021-11-30

Family

ID=44210117

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
BRPI0511624-4A BRPI0511624B1 (pt)	2004-05-28	2005-05-17	Anticorpo monoclonal que se liga à proteína psca, uso do mesmo, hibridoma, vetor, composição farmacêutica, bem como ensaio e método para detecção da presença de uma proteína psca em uma amostra biológica
BR122018073034-0A BR122018073034B1 (pt)	2004-05-28	2005-05-17	Anticorpos e moléculas relacionadas que se ligam à proteínas de psca
BRPI0520902-1A BRPI0520902B1 (pt)	2004-05-28	2005-05-17	Anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo que se liga a proteínas psca para diagnóstico de câncer, método para produção dos mesmos, hibridoma, polinucleotídeo, vetor, composição, ensaio para detectar a presença de uma proteína psca e método de detecção de uma proteína psca

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
BRPI0511624-4A BRPI0511624B1 (pt)	2004-05-28	2005-05-17	Anticorpo monoclonal que se liga à proteína psca, uso do mesmo, hibridoma, vetor, composição farmacêutica, bem como ensaio e método para detecção da presença de uma proteína psca em uma amostra biológica
BR122018073034-0A BR122018073034B1 (pt)	2004-05-28	2005-05-17	Anticorpos e moléculas relacionadas que se ligam à proteínas de psca

Country Status (6)

Country	Link
KR (2)	KR101282396B1 (pt)
CN (1)	CN102344493B (pt)
BR (3)	BRPI0511624B1 (pt)
IL (1)	IL214210A (pt)
NO (1)	NO341404B1 (pt)
SI (1)	SI1753871T1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2442919T3 (es)	2007-03-27	2014-02-14	Immunovia Ab	Firma/marcadores de proteínas para la detección de adenocarcinoma
TR201900694T4 (tr) *	2012-08-23	2019-02-21	Agensys Inc	158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
BR112015013700A8 (pt)	2012-12-13	2020-02-18	Inovio Pharmaceuticals Inc	composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
GB201319878D0 (en) *	2013-11-11	2013-12-25	Immunovia Ab	Method, Array and use thereof
EP3080159A4 (en)	2013-12-13	2017-08-02	The Trustees Of The University Of Pennsylvania	Dna antibody constructs and method of using same
CN107427566B (zh)	2014-12-01	2021-08-17	宾夕法尼亚大学理事会	Dna抗体构建体及其使用方法
GB202010970D0 (en)	2020-07-16	2020-09-02	Immunovia Ab	Methods, arrays and uses thereof
CN119930826A (zh) *	2023-11-02	2025-05-06	重庆精准生物产业技术研究院有限公司	针对psca的全人源单链抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6258939B1 (en) *	1997-03-10	2001-07-10	The Regents Of The University Of California	PSCA antibodies and hybridomas producing them
US6267960B1 (en) *	1997-03-10	2001-07-31	The Regents Of The University Of California	PSCA: prostate stem cell antigen
US6541212B2 (en) *	1997-03-10	2003-04-01	The Regents Of The University Of California	Methods for detecting prostate stem cell antigen protein
JP4028237B2 (ja) *	1999-10-29	2007-12-26	ジェネンテック・インコーポレーテッド	抗前立腺幹細胞抗原（ｐｓｃａ）抗体組成物及び使用方法

2005
- 2005-05-17 SI SI200532000T patent/SI1753871T1/sl unknown
- 2005-05-17 KR KR1020117010832A patent/KR101282396B1/ko not_active Expired - Lifetime
- 2005-05-17 BR BRPI0511624-4A patent/BRPI0511624B1/pt not_active IP Right Cessation
- 2005-05-17 BR BR122018073034-0A patent/BR122018073034B1/pt active IP Right Grant
- 2005-05-17 CN CN201110118165.5A patent/CN102344493B/zh not_active Expired - Lifetime
- 2005-05-17 BR BRPI0520902-1A patent/BRPI0520902B1/pt active IP Right Grant
2006
- 2006-12-28 KR KR1020067027763A patent/KR101215611B1/ko not_active Expired - Lifetime
2011
- 2011-04-29 NO NO20110647A patent/NO341404B1/no unknown
- 2011-07-20 IL IL214210A patent/IL214210A/en active IP Right Grant

Also Published As

Publication number	Publication date
SI1753871T1 (sl)	2016-01-29
BRPI0511624B1 (pt)	2022-02-08
CN102344493B (zh)	2014-09-03
BR122018073034B1 (pt)	2021-10-13
KR20070047251A (ko)	2007-05-04
IL214210A0 (en)	2011-08-31
KR101282396B1 (ko)	2013-07-04
KR20110056564A (ko)	2011-05-30
NO20110647L (no)	2006-12-19
BR122018073034B8 (pt)	2022-10-11
BRPI0520902B1 (pt)	2021-11-30
CN102344493A (zh)	2012-02-08
NO341404B1 (no)	2017-10-30
KR101215611B1 (ko)	2012-12-28
IL214210A (en)	2013-01-31
BRPI0511624A (pt)	2008-01-02

Publication	Publication Date	Title
BRPI0308585B8 (pt)	2021-05-25	anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
BRPI0818437A2 (pt)	2015-05-12	Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
BRPI0821682A2 (pt)	2015-06-16	Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.
BRPI0816117B8 (pt)	2021-05-25	anticorpo monoclonal isolado ou fragmento do mesmo, composiçãofarmacêutica, kit para tratamento de desordens relacionadas com colesterol, e, uso de uma proteína de ligação de antígeno ou de um anticorpo monoclonal ou fragmento do mesmo
EA201100527A1 (ru)	2011-10-31	Биологические продукты
BR112012009846A2 (pt)	2017-02-21	ensaios para detecção de anticorpos específicos para anticorpos anti-ige terapêuticos e seu uso em anafilaxia
WO2006086208A3 (en)	2007-04-26	5-fluoro-uracil immunoassay
WO2007061793A3 (en)	2007-08-09	Modified cardiolipin and uses therefor
ATE464374T1 (de)	2010-04-15	Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
HRP20161398T1 (hr)	2016-12-16	Anti-idiotip-protutijelo protiv protutijela koje je protiv amiloid-beta-peptida
EP3665187A4 (en)	2021-04-21	TEST PROCEDURES FOR IMPROVED ANALYTE DETECTION
EP1708745A4 (en)	2007-12-19	ANTIBODIES FOR ONCOGENIC STRAINS OF HPV AND METHOD FOR THEIR USE
ATE412179T1 (de)	2008-11-15	Nachweis von arzneistoffen der methamphetamingruppe
WO2008101177A3 (en)	2009-01-29	Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
DE502005010086D1 (de)	2010-09-23	Monoklonaler antikörper gegen humanen frizzled-4-rezeptor
EP1643894A4 (en)	2009-06-10	METHOD, KITS AND ANTIBODIES FOR THE DETECTION OF PARATHYROID
WO2006102200A3 (en)	2007-05-31	Docetaxel immunoassay
WO2008054724A3 (en)	2008-10-30	Monoclonal antibodies against osteopontin
EP4046714A4 (en)	2023-11-22	MICROFLUIDIC CHIP FOR DETECTING ANALYTES
BRPI0520902A2 (pt)	2011-10-25	Anticorpo monoclonal ou fragmento de ligação a antigeno do mesmo que se liga a proteinas psca para disgnostico de cancer, metodo para produção dos mesmos, hib'ridoma, polinucleotideo, vetor, celula, composição, ensaio para detectar a presença de uma proteina'psca e metodo de detecção de uma proteina psca
WO2003046140A3 (en)	2003-07-31	Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
EP1891108A4 (en)	2010-01-13	PSP94 DIAGNOSTICS AND ASSAYS
ATE405837T1 (de)	2008-09-15	Festphase immunochromatographische testverfahren
CA2589054A1 (en)	2006-06-29	Detection of a therapeutic antibody in an experimental animal
WO2004084841A3 (en)	2009-09-03	Novel anti-feline albumin antibodies and methods of detecting early renal disease

Legal Events

Date	Code	Title	Description
2013-04-02	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE 7A. ANUIDADE.
2013-06-25	B08H	Application fees: decision cancelled [chapter 8.8 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2204 DE 02/04/2013.
2015-09-08	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-03-20	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-07-31	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-09-18	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2021-05-18	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-10-05	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-11-30	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/05/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.